Calcium antagonists and cancer. Is there really a link?

Drug Safety

Volumn 18, Issue 1, 1998, Pages 1-7

  Howes, Laurence G ^a,b   Edwards, Christina T ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; DILTIAZEM; ISRADIPINE; NIFEDIPINE; VERAPAMIL;

ADULT; AGED; CANCER; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CALCIUM CHANNEL BLOCKERS; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0031965043     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818010-00001     Document Type: Review

References (38)

1. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-7
2. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-99
3. Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80: 1438-47
4. Walker AM, Stampfer MJ. Observational studies of drug safety. Lancet 1996; 348: 489
5. Saracci R, Trichopoulos D. Aetiological leads. In: Peckham M, Pinedo HM, Veronesi V, editors. Oxford textbook of oncology. Oxford: Oxford University Press, 1995: 167-74
6. Framer JA, Grotto A Jr. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E, editor. Philadelphia: Saunders, 1997: 1126-60
7. Dyer AR, Stamler J, Berkson DM, et al. High blood-pressure: A risk factor for cancer mortality? Lancet 1975; 1 (7915): 1051-6
8. Bel Buono R, Wright N. The growth of human tumors. In: Peckham M, Pinedo HM, Veronesi V, editors. Oxford textbook of oncology. Oxford: Oxford University Press, 1995: 3-11
9. Yuspa SH, Shield S. Etiology of cancer: chemical factors. In: De Vita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 185-202
10. Connor J, Sawczuk IS, Benson MC, et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 118-30
11. 2+ channels exposed to serum from patients with type I diabetes. Science 1993; 261: 86-90
12. 2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993; 7: 453-63
13. Kondo S, Yin D, Morimura T, et al. Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 1995; 71: 282-9
14. 3 carcinoma cell growth in culture by calcium, calmodulin and prostaglandins. Cancer Res 1985; 45: 396-405
15. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992; 52: 2413-8
16. Onoda JM, Diglio C, Taylor JD, et al. Antimetastatic effect of the calcium channel blocker dilantizem [abstract]. Proc Ann Meet Am Assoc Cancer Res 1984; 25: 351
17. Honn KV, Onoda JM, Diglio CA, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis 1984; 2: 61-77
18. Onoda JM, Sloan BF, Taylor JD, et al. Calcium channel blockers: inhibitors of tumor cell-platelet-endothelial cell interactions. In: Hemostatic mechanisms and metastases. Hunn KV, Sloane BF, editors. Boston (MA): Martinus Nijhoff, 1984: 244-58
19. Honn KV, Onoda JM, Diglio CA, et al. Calcium channel blockers: potential antimetastatic agents. Proc Soc Exp Biol Med 1983; 174 (1): 16-9
20. Bando H, Yamashita T, Tsubura E. Effects of antiplatelet agents on pulmonary metastases. Gann 1984; 75 (3): 284-91
21. Gastpar H, Ambrus JL, Ambrus CM. Platelet aggregation inhibitors in the prevention of metastasis in neoplastic disease: a review of experimental and clinical investigations. J Med 1981; 12: 15-33
22. Tsuruo T, Iida H, Makishima F, et al. Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. Cancer Chemother Pharmacol 1985; 14: 30-3
23. Zacharski LR, Moritz TE, Haakenson CM, et al. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest 1990; 8: 451-8
24. Tsuruo T, Iida H, Nojiri M, et al. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983; 43 (6): 2905-10
25. Slater LM, Murray SL, Wetzel MW, et al. Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma. J Clin Invest 1982; 70 (5); 1131-4
26. Tsuruo T, Iida H, Naganuma K, et al. Promotion of verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. Cancer Res 1983; 43 (2): 808-13
27. Slater L, Murray S, Wetzel M, et al. Verapamil potentiation of VP-16-213 in acute lymphatic leukemia (ALL) in vivo and reversal of pleiotropic drug resistance (PDR) [abstract]. Proc Ann Meet Am Assoc Cancer Res 1985; 26: 336
28. Onoda JM, Jacobs JR, Taylor JD, et al. Cisplatinum and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastases. Cancer Lett 1986; 30: 181-8
29. Braun S, Boyko V, Behar S, et al. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. JACC 1996; 28 (1): 7-11
30. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8
31. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). JAMA 1996; 27: 785-91
32. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-45
33. Olsen JH, Storensen HT, Friis S, et al. Cancer risk in users of calcium channel-blockers [abstract]. Pharmacoepidemiol Drug Saf 1997; 6 (Suppl. 2): 31
34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293-302
35. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-91
36. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12
37. Hole DJ, Hawthorne VM, Isles CG, et al. Incidence of and mortality from cancer in hypertensive patients. BMJ 1993; 306: 609-11
38. Pahor M, Guralnik JM, Corti MC, et al. Long term survival and use of antihypertensive medications in the elderly. J Am Geriat Soc 1995; 43 (11); 1191-7